Biophytis (BPTSY) AI Stock Analysis

• Market Cap: $3.37M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: N/A
• EPS Growth: -4662.17%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -15420.51
• Shares Outstanding: 2,016,346
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: <0.01
• Price to Book (P/B): -3.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $15.00
• Price Target Upside: 886.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 35 Underperform
• Price Target: ―

Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.

Biophytis Business Overview & Revenue Model

Company Description

Biophytis (BPTSY) is a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases. The company's product pipeline includes drug candidates targeting neuromuscular diseases such as sarcopenia and other conditions like severe respiratory failure in COVID-19 patients. Biophytis utilizes its proprietary technology platforms to advance its research and development efforts in these areas.

How the Company Makes Money

Biophytis generates revenue through the development and potential commercialization of its drug candidates. The company's revenue model primarily focuses on licensing agreements, partnerships, and collaborations with other pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties based on product sales. Additionally, Biophytis may receive funding from grants and research collaborations to support its clinical trials and research initiatives. The success of its revenue model is contingent upon the progression and approval of its drug candidates through clinical trials and regulatory processes.

Biophytis Financial Statement Overview

Summary

Biophytis is experiencing significant financial distress characterized by continuous operating losses, negative equity, and reliance on external financing. The absence of revenue poses a major challenge, while the ongoing cash burn and high debt levels present substantial risks to financial stability.

Income Statement

Biophytis has faced consistent financial challenges with no revenue generation over the past years. The company has significant negative EBIT and EBITDA margins due to high operating losses. Net profit margins remain deeply negative, reflecting the ongoing unprofitability.

Balance Sheet

The balance sheet reveals significant financial instability with negative stockholders' equity, indicating a concerning level of leverage. The debt-to-equity ratio cannot be calculated due to negative equity, and the company relies heavily on debt financing. Total liabilities exceed total assets, further highlighting financial vulnerability.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, indicating poor cash generation capabilities. However, a reduction in negative free cash flow over time suggests some improvements in cash management. The company is heavily reliant on financing activities for cash inflow.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-653.00K	-803.00K	-484.00K	-311.00K	-280.00K	-262.00K
	EBIT
-12.20M	-14.33M	-23.27M	-26.82M	-13.94M	-15.68M
	EBITDA
-11.66M	-13.80M	-23.04M	-26.50M	-13.66M	-15.42M
	Net Income Common Stockholders
-15.07M	-17.03M	-24.22M	-31.16M	-25.52M	-18.95M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.30M	5.93M	11.64M	25.16M	18.77M	6.81M
	Total Assets
8.71M	11.96M	21.99M	36.26M	27.21M	17.67M
	Total Debt
7.19M	6.08M	12.13M	15.38M	9.10M	15.24M
	Net Debt
5.00M	514.00K	1.07M	-8.55M	3.25M	8.91M
	Total Liabilities
15.13M	15.85M	23.90M	30.56M	20.38M	25.20M
	Stockholders Equity
-6.38M	-3.86M	-1.88M	5.74M	6.86M	-7.50M
Cash Flow		Free Cash Flow
-5.96K	-13.09M	-19.13M	-24.14M	-10.08M	-15.55M
	Operating Cash Flow
―	-12.87M	-18.99M	-23.80M	-9.86M	-15.27M
	Investing Cash Flow
―	370.00K	-17.00K	12.16M	-12.71M	-278.00K
	Financing Cash Flow
2.58K	7.03M	6.13M	29.71M	22.07M	7.50M

Biophytis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTSY, the sentiment is Negative. The current price of 1.52 is below the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.79, and below the 200-day MA of 3.20, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 38.35 is Neutral, neither overbought nor oversold. The STOCH value of 62.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPTSY.

Biophytis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	77 Outperform	$366.74M	9.90	531.78%	―	68.74%	―
KNSA	75 Outperform	$2.02B	―	-3.81%	―	59.45%	-290.38%
VRNA	68 Neutral	$7.87B	―	-72.73%	―	―	-157.53%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
AKTX	44 Neutral	$33.81M	―	-197.11%	―	―	―
BPTSY	35 Underperform	$3.37M	―	441.43%	―	―	-4662.17%